Trust Co. of Vermont Has $449,000 Stock Position in Boston Scientific Corporation $BSX

Trust Co. of Vermont decreased its stake in Boston Scientific Corporation (NYSE:BSX) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,176 shares of the medical equipment provider’s stock after selling 150 shares during the period. Trust Co. of Vermont’s holdings in Boston Scientific were worth $449,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the last quarter. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter worth $27,000. Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the second quarter worth $37,000. Finally, Activest Wealth Management lifted its position in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 373 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $95.78 on Thursday. The stock has a 50-day simple moving average of $103.30 and a 200 day simple moving average of $102.08. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The stock has a market capitalization of $141.91 billion, a price-to-earnings ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the business posted $0.62 earnings per share. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Barclays raised their target price on Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Truist Financial raised their target price on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday. BTIG Research raised their target price on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Leerink Partnrs raised Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $120.67.

Insiders Place Their Bets

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.